https://www.immunomedics.com/

Contact Information:

Rob Kim
rkim@Immunomedics.com
425-802-9809

Zoom hours available during breaks: https://engage.veeva.com/m.html?j=5661646687

• 7:00am - 8:00am CT
• 9:30am - 10:30am CT
• 12:15pm - 1:15pm CT
• 2:45pm - 3:45pm CT

Virtual Exhibit Hall Home

Immunomedics is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping transform the lives of people with hard-to-treat cancers. Our proprietary ADC binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. For additional information, please visit our website, Immunomedics.com.

TRODELVY Prescribing Information 

TRODELVY Clinical Trial Results 

TRODELVY iPub presented by Dr. Hope S. Rugo Will